KF
CAPR icon

Krilogy Financial’s Capricor Therapeutics CAPR Stock Holding History

Krilogy Financial’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,800
Closed -$160K – 938
2025
Q3 		$160K Sell
25,800
-15,000
-37% -$110K 0.01% 831
2025
Q2 		$405K Buy
40,800
+18,000
+79% +$190K 0.02% 226
2025
Q1 		$216K Buy
22,800
+2,000
+10% +$27.8K 0.01% 220
2024
Q4 		$287K Buy
+20,800
New +$364K 0.02% 210

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Krilogy Financial's CAPR Position: Q4 2025 in Review

Krilogy Financial sold out of Capricor Therapeutics (CAPR) in Q4 2025, closing a stake of 25,800 shares — an estimated $160K sold.

Krilogy Financial first reported a position in CAPR in Q4 2024 and held it in 4 quarters. The position peaked at $405K in Q2 2025. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

  • Krilogy Financial reported no remaining Capricor Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Krilogy Financial sold 25,800 Capricor Therapeutics shares in Q4 2025, an estimated $160K.
  • Krilogy Financial first reported a position in Capricor Therapeutics in Q4 2024 and held it in 4 quarters.
  • Krilogy Financial's Capricor Therapeutics position peaked at $405K in Q2 2025.
  • 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on Krilogy Financial's 13F filing for Q4 2025, filed 27 Jan 2026.